HCR Monthly Blog

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

April 2nd, 2014 Tom Norton

Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s stock had taken a dive [transcript p. 94]: Sen. Lieberman: Do you have any doubt that the actions that were at least included in the original Administration (Clinton Health Care) proposal, such read more


‘Close Call’ for American Rx Marketers on Medicare Part D

March 12th, 2014 Tom Norton

As the U.S. heads towards a public market place in which Medicare, Medicaid, CHIPs, VA, and now Obamacare will shortly comprise almost 70% of the American healthcare market (http://goo.gl/SLRuC), American Rx marketers recently endured a “close call” with the U.S.  Department of Health and Human Services over the arbitrary deletion of dozens of key drugs read more


Bringing New Rx Drugs to Market in 2014

February 19th, 2014 Tom Norton

I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide position. Today, based read more


2014: End of the Road for the American Rx Salesperson?

January 30th, 2014 Tom Norton

“The only thing you’ve got in this world is what you can sell.” Willy Loman Death of a Salesman adobe cs6 download During my years with two major U.S. pharmaceutical companies, some of the most interesting individuals I got to know were field salespersons.  Certainly one of my favorites was a gentleman I met early read more